Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3

Status

Completed 173Unknown 52Terminated 28Withdrawn 6Recruiting 6Active not recruiting 6Not yet recruiting 1

Sponsor Class

OTHER 5NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6

Conditions

Multiple Myeloma 5Neoplasms, Plasma Cell 1

Interventions

pembrolizumab 438Carboplatin 321Nivolumab 293Cyclophosphamide 285Specimen Handling 257Paclitaxel 249Magnetic Resonance Spectroscopy 249Cisplatin 248Radiotherapy 218Dexamethasone 183Gemcitabine 177Biopsy 177durvalumab 169atezolizumab 149Doxorubicin 140Rituximab 138Lenalidomide 135Docetaxel 131Ipilimumab 130Bevacizumab 128Radiation 121Capecitabine 117Etoposide 116Oxaliplatin 114Fluorouracil 110Pemetrexed 109Radiosurgery 108fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Thalidomide × Clear all
NCT00734877 2026-05-22

TT4B

University of Arkansas

Phase 3 Active not recruiting
382 enrolled
Plasma cell

Multiple Myeloma

NCT00869232 2026-05-22

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

University of Arkansas

Phase 2 Active not recruiting
90 enrolled
Plasma cell

Multiple Myeloma

NCT00871013 2026-05-11

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

University of Arkansas

Phase 2 Active not recruiting
160 enrolled
Plasma cell

Neoplasms, Plasma Cell

NCT00602641 2026-04-29

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
306 enrolled 12 charts
Plasma cell

Multiple Myeloma

NCT00572169 2026-02-05

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

University of Arkansas

Phase 3 Active not recruiting
177 enrolled
Plasma cell

Multiple Myeloma

NCT03004287 2025-09-10

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

University of Arkansas

Phase 2 Active not recruiting
50 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡